MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
2) Consolidators: Medical Device Sector
*Consolidators: Surgical Technology
Edwards Lifesciences Corporation (NYSE: EW)
Organization & Developments: Edwards Lifesciences
Parents
Edwards Lifesciences Corporation (NYSE: EW)
Children
*DEVELOPS PRODUCTS TO TREAT ADVANCED CARDIOVASCULAR DISORDERSINCLUDING HEART VALVE AND PERIPHERAL VASCULAR DISEASE.
*EDWARDS EVOQUE TRICUSPID VALVE REPLACEMENT SYSTEM
*Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring.
*Edwards Lifesciences: Business Areas
*Embol-X
*EW, Edwards Lifesciences Cp
*Heart valve maker
*Manufactures products in Irvine, Draper, Utah, and several global locations, including Dominican Republic, Puerto Rico, Singapore and Switzerland.
2011: Marvels of Medical Technology: Sapien Transcatheter heart valve (2011)
2011: No. 1 maker of heart valves (2011)
2014: Edwards Lifesciences Corporation Wins $392 Million patent-infringement lawsuit against Medtronic (2014)
2015: 1. Edwards Lifesciences: 34.91% Profit Margin
2015: Edwards Lifesciences Hits High As Street Lauds Buyout EW MDT
2016: Edwards Lifesciences Soars To New High As Heart Valve Aces Trial
2016: Edwards Lifesciences: After A Sharp Sell-Off, An Insider Makes A Million Dollar Purchase - Edwards Lifesciences Corp (NYSE:EW)
2016: Edwards Q3 Earnings Disappoint
2016: Edwards up 13% on Sapien TAVR data in intermediate-risk heart patients
2016: Looking for a Growth Stock? Why It is Time to Focus on Edwards Lifesciences (EW)
2017: VA_65--Edwards EV1000 Platform Clear Sight
2017: VA_65--sources sought notice Edwards Life Science EV1000CS Platform
2018: Edwards Life Sciences_Large Companies Eye Collaboration as Entry into AI
2018: Edwards Lifescience_Will A New Approval Help This Medical Stock Approach A Breakout?
2018: Edwards Lifesciences (EW)_ Can This IBD 50 Stock Stem Its Share Losses In Heart-Valve Replacements?www.investors.com
2018: VA_Edwards LifeScience_65--(TAVR) Transcatheter Heart Valve Replacement
2019: Edwards Lifesciences Beats, Raises And Surges: Analysis_seekingalpha.com
2019: Edwards Lifesciences: Thoughts On Its Growth Plans And Valuation_seekingalpha.com
2020: Leading Medtech Stock Hammered On Potential Slowdown In Heart Devices_www.investors.com
2022: Edwards Lifesciences: Catalysts For 2023 And Beyond_ seekingalpha.com
2022: Edwards Lifesciences: Opening My Heart_ seekingalpha.com
2022: Edwards Lifesciences: Seeking 60% Upside For Potential Exit At $160 Per Share_seekingalpha.com
2022: Edwards’ Sapien 3 transcatheter pulmonary valve system with Alterra adaptive present is a catheter-based stent and artificial heart valve for treating patients whose right ventricular outflow tract becomes too leaky.
2023: Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
2023: Edwards’ TAVR results hurt by pandemic aftereffects and competition in Q2
2024: BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader
2024: Edward Lifesciences: Still Not A Buy But Getting Closer_ seekingalpha.com
2024: Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
2024: Edwards Lifesciences: Evoque Transcatheter Tricuspid Valve Replacement System (also nominated in 2024)
2024: Edwards Lifesciences: Sapien 3 Ultra Resilia Transcatheter Aortic Heart Valve (also nominated in 2024)
2025: Edward Lifesciences: A Closer Look At Growth And Valuation
2025: Edwards announces $500M accelerated share repurchase
2025: Edwards Lifesciences raises 2025 sales growth outlook to 9-10% amid robust TAVR and TMTT momentum
2025: Edwards Lifesciences: A Market Leader Stuck In 'Hold' Mode Despite Solid Growth
2025: Edwards Lifesciences: Inflection Incoming, But When? (NYSE:EW)
2025: Edwards Lifesciences: Overbought Given Current Growth Prospects
2025: Edwards Lifesciences: Overbought Given Current Growth Prospects
2025: Edwards Lifesciences: With A Heart Beating Strong And Steady
Jumps
*Key People: Edwards Lifesciences
Finance & Acquisitions: Edwards Lifesciences